| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg | |||
| Other Sizes |
| Targets |
PI3Kα (IC50 = 4.8 μM)
Brevianamide F's mechanism of action is not fully understood. It has been shown to exhibit antimicrobial activity against various bacterial and fungal strains, as well as antiviral activity against certain viruses. Its cytotoxic effects on cancer cell lines have also been reported, suggesting it may interact with cellular targets involved in cell proliferation and survival. |
|---|---|
| ln Vitro |
Both MSSA and MRSA are moderately active against by brevianamide F[1].
Brevianamide F has demonstrated antimicrobial activity against a range of microorganisms, including Staphylococcus aureus, Escherichia coli, and Candida albicans. It has also shown antiviral activity against herpes simplex virus and influenza virus. In addition, brevianamide F exhibits cytotoxic activity against various cancer cell lines, including HeLa and HL-60 cells. |
| ln Vivo |
In vivo activity data for brevianamide F is limited. As a natural product, its potential therapeutic applications have been explored in preclinical models. Studies have investigated its antimicrobial and anticancer efficacy in animal models. However, more research is needed to fully characterize its in vivo activity and pharmacokinetic properties.
|
| Enzyme Assay |
In vitro enzyme assays for brevianamide F are not specific. Its biological activities are typically assessed using cell-based assays for antimicrobial, antiviral, or cytotoxic activity. The compound's mechanism of action may be studied by identifying its molecular targets using techniques such as affinity chromatography or chemical proteomics.
|
| Cell Assay |
In vitro cellular assays for brevianamide F involve treating microbial cells or cancer cell lines with the compound and measuring cell viability or growth inhibition. Antimicrobial activity is assessed by measuring the zone of inhibition or the minimum inhibitory concentration (MIC). Cytotoxicity is assessed using metabolic assays such as MTT or by counting viable cells.
|
| Animal Protocol |
In vivo animal studies for brevianamide F are limited. Studies may involve administration to animal models of infection or cancer to assess its efficacy. The compound's pharmacokinetic properties and toxicity profile would also be evaluated in these studies.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for brevianamide F is limited. As a natural product, its absorption, distribution, metabolism, and elimination have not been extensively characterized. Further studies are needed to determine its bioavailability and half-life in vivo.
|
| Toxicity/Toxicokinetics |
Preclinical toxicity studies of brevianamide F are limited. Its safety profile has not been extensively evaluated. The compound's potential toxicity would need to be assessed in animal models before any clinical development.
|
| References |
|
| Additional Infomation |
Brevianamide F is a pyrrolopyrazine compound with the structure hexahydropyrrolo[1,2-a]pyrazine-1,4-dione, containing an indole-3-ylmethyl substituent at the 3-position (3S,8aS-diastere, prepared by the cyclocondensation of L-tryptophan and L-proline). It is a metabolite. It belongs to the pyrrolopyrazine class of compounds, specifically the indole class, and is also a dipeptide. Brevianamide F has been reported to be detected in Aspergillus versicolor, Exophiala pisciphila, and other organisms with relevant data.
Brevianamide F is a fungal metabolite belonging to the diketopiperazine class of compounds. It has been studied for its diverse biological activities, including antimicrobial, antiviral, and cytotoxic properties. Its structure features a unique spiro-oxindole core, which has made it a target for total synthesis. Further research is needed to fully characterize its mechanism of action and therapeutic potential. |
| Molecular Formula |
C16H17N3O2
|
|---|---|
| Molecular Weight |
283.331
|
| Exact Mass |
283.132
|
| Elemental Analysis |
C, 67.83; H, 6.05; N, 14.83; O, 11.29
|
| CAS # |
38136-70-8
|
| Related CAS # |
38136-70-8
|
| PubChem CID |
181567
|
| Appearance |
White to off-white solid powder
|
| Boiling Point |
633.2°C
|
| LogP |
1.413
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
21
|
| Complexity |
453
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
O=C1[C@]([H])(C([H])([H])C2=C([H])N([H])C3=C([H])C([H])=C([H])C([H])=C23)N([H])C([C@]2([H])C([H])([H])C([H])([H])C([H])([H])N21)=O
|
| InChi Key |
RYFZBPVMVYTEKZ-KBPBESRZSA-N
|
| InChi Code |
InChI=1S/C16H17N3O2/c20-15-14-6-3-7-19(14)16(21)13(18-15)8-10-9-17-12-5-2-1-4-11(10)12/h1-2,4-5,9,13-14,17H,3,6-8H2,(H,18,20)/t13-,14-/m0/s1
|
| Chemical Name |
(3S,8aS)-3-(1H-indol-3-ylmethyl)-2,3,6,7,8,8a-hexahydropyrrolo[1,2-a]pyrazine-1,4-dione
|
| Synonyms |
Brevianamide F
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 50~57 mg/mL (176.5~201.2 mM)
Ethanol: ~19 mg/mL (~67.1 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (8.82 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (8.82 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (8.82 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.5295 mL | 17.6473 mL | 35.2945 mL | |
| 5 mM | 0.7059 mL | 3.5295 mL | 7.0589 mL | |
| 10 mM | 0.3529 mL | 1.7647 mL | 3.5295 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
